Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 2, p. s4, 2022. DOI: 10.25251/skin.6.supp.4. Disponível em: https://skin.dermsquared.com/skin/article/view/1520. Acesso em: 22 jul. 2025.